
200 First Street SW
Rochester, Minnesota 55905
507-284-2511

Morie A. Gertz, M.D.
Chair
Department of Internal Medicine
Consultant, Division of Hematology
*Roland Seidler, Jr., Professor of the
Art of Medicine*
507-284-2865, Fax 507-266-4972

October 30, 2020

Chair, The Council of Scientific Excellence in Warsaw

Dear Committee:

I am pleased to be able to support the application for Artur Jurczyszyn for academic advancement to Professor of Medicine. Dr. Jurczyszyn is well-known in the multiple myeloma community as he serves as a member of the International Myeloma Society Working Group. He has written extensively on topics associated with multiple myeloma including most recently the role of serum free light chain in the diagnosis of monoclonal gammopathies and the role of the bone marrow micro environment in the pathogenesis of multiple myeloma. He has done important basic science research, published in *Leukemia Research* on the plasma fatty acid profile in multiple myeloma, and has served on a number of consensus panels to which he has been appointed in recognition of his expertise in the management of multiple myeloma. He has been an important force in the organization of myeloma conferences at the University and has brought a number of prestigious speakers to the University to hold all day symposia on multiple myeloma. His publication track record has actually accelerated in the past four years as he gains greater expertise in the field of multiple myeloma. Over the past 4 years we have collaborated on a number of projects regarding rare aspects of multiple myeloma. He was a member of the panel that developed guidelines for the management of relapsed multiple myeloma for the international myeloma working group. He is a recognized expert on the management and outcomes of secondary plasma cell leukemia. He was also the seen your author on an important trial on extramedullary relapse in multiple myeloma. Finally he was the 1st author of an important global trial describing outcomes with cutaneous involvement in multiple myeloma. He is considered a leading authority of multiple myeloma in Poland. A number of these trials were presented at the annual American society of Hematology an European Hematology Association meetings. He is published in important hematologic journals including *leukemia*, *leukemia and lymphoma*, *blood*, the *American Journal of Hematology*, the *Journal of Clinical Medicine* and the *Journal of Clinical Oncology*.

He is a recognized clinical investigator and has been a co-author on important treatment abstracts on new agents for the treatment of multiple myeloma, including, Elotuzumab and Daratumumab. He is an active educational participant for medical residents and medical students at the University. I believe he would fulfill the criteria for advancement to Professor at our institution and I can recommend him without reservation for advancement.

Further questions can be directed to me.

Sincerely yours,



Morie Gertz, M.D., M.A.C.P.
Roland Seidler, Jr., Professor of the Art of Medicine
Chair Emeritus, Department of Medicine
Mayo Distinguished Clinician

mag/lis